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Background: Appropriate disposition of emergency department (ED) patients with chest pain is dependent on
clinical evaluation of risk. A number of chest pain risk stratification tools have been proposed. The aim of this study
was to compare the predictive performance for major adverse cardiac events (MACE) using risk assessment tools
from the National Heart Foundation of Australia (HFA), the Goldman risk score and the Thrombolysis in Myocardial
Infarction risk score (TIMI RS).
Methods: This prospective observational study evaluated ED patients aged ≥30 years with non-traumatic chest pain
for which no definitive non-ischemic cause was found. Data collected included demographic and clinical information,
investigation findings and occurrence of MACE by 30 days. The outcome of interest was the comparative predictive
performance of the risk tools for MACE at 30 days, as analyzed by receiver operator curves (ROC).
Results: Two hundred eighty-one patients were studied; the rate of MACE was 14.1%. Area under the curve (AUC) of
the HFA, TIMI RS and Goldman tools for the endpoint of MACE was 0.54, 0.71 and 0.67, respectively, with the difference
between the tools in predictive ability for MACE being highly significant [chi2 (3) = 67.21, N = 276, p < 0.0001].
Conclusion: The TIMI RS and Goldman tools performed better than the HFA in this undifferentiated ED chest pain
population, but selection of cutoffs balancing sensitivity and specificity was problematic. There is an urgent need for
validated risk stratification tools specific for the ED chest pain population.
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Chest pain remains one of the most common presenting
complaints in patients presenting to emergency depart-
ments (ED), with >100,000 patients being hospitalized
each year in Australia with acute coronary syndromes
(ACS) [1]. The morbidity, mortality and economic costs
associated with this constitute a significant burden on the
Australian health system [2]. In these patients, use of risk
stratification tools to predict risk of death, cardiac compli-
cations and the pre-test probability of ACS has been dem-
onstrated to aid clinicians in appropriate prioritizing of
patients for investigations [3,4] and assists in identification
of those at higher risk who might benefit most from* Correspondence: anne-maree.kelly@wh.org.au
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in any medium, provided the original work is ppotent drug therapies or an early invasive therapeutic ap-
proach [5-10]. Risk stratification tools have further been
shown to allow patients to be better informed of their
prognosis [7], improve cost-effectiveness while minimizing
unnecessary treatment complications [11] and reduce un-
necessary admissions to inpatient monitored beds, with-
out increasing complications, thereby potentially having a
positive impact on access block [3,6,12,13].
Recently, in Queensland, a suite of clinical pathways
for the management of patients presenting to public
hospitals with chest pain was developed [14], with appli-
cation incentivized by practice improvement payments
[15]. These pathways rely on risk stratification utilizing
the National Heart Foundation of Australia risk stratifi-
cation tool (HFA), perhaps the most prominent risk
stratification utilized in Australia [16]. Although the in-
dividual components of this tool are evidence based andan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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it was designed for risk stratification of patients with
ACS rather than for the undifferentiated ED chest pain
population. There are conflicting data regarding its per-
formance in ED chest pain populations [17,18].
The aim of this prospective observational study was to
compare the performance of three methods of risk
stratification, namely, the National Heart Foundation of
Australia risk stratification tool (HFA) [16], the Goldman
score [6] and the Thrombolysis in Myocardial infarction
(TIMI) risk score [19] for prediction of a composite out-
come of major adverse cardiac events (MACEs) within
30 days of ED attendance.
Methods
This was a prospective, cohort study undertaken at a
single tertiary referral ED. Patients presenting to the ED
with non-traumatic chest pain during the preceding
48 h and aged >30 years were eligible for inclusion in
the study. Exclusion criteria were the presence of a de-
finitive non-ischemic cause for chest pain, isolated
angina-equivalent symptoms, trauma-related chest pain,
cardiac arrest on arrival to the ED, patients with ECG
criteria for ST-elevation myocardial infarction (MI) on
arrival to the ED and inability to provide informed
consent.
Data collection occurred during the ED presentation
on weekdays that a trained research nurse was available.
Follow-up was undertaken by both review of medical re-
cords utilizing a standardized data collection tool and a
phone call to the patient (or proxy if the patient was not
contactable) employing a structured interview at 72 h and
30 days. A single emergency physician, blinded at the time
to the patient outcomes, retrospectively undertook the
risk stratification process using the prospectively collected
data items and initial ED-acquired electrocardiogram.
All patients included in the study had their cardiac risk
determined by each of three methods of risk stratification
utilizing findings on presentation to the ED (see Table 1).
The HFA [16] and Goldman tools classify patients into risk
groups with nominal descriptors (e.g., high, low), while the
TIMI risk tool derives a score out of seven [9,17].
The primary outcome of interest was MACE within
30 days of ED presentation. MACE components were
defined utilizing the American College of Cardiology
Clinical Data Standards definitions [20] and included
acute myocardial infarction (prevalent and incident), re-
current ischemia requiring urgent revascularization, car-
diogenic shock, ventricular arrhythmia requiring emergent
intervention or high-grade atrioventricular block requiring
treatment, cardiac arrest and all-cause mortality.
For analysis, continuous variables with normal distribu-
tion were expressed as medians and interquartile ranges;categorical data were presented as percentages. Group dif-
ferences in continuous and categorical variables are com-
pared with Kruskal-Wallis and chi-square tests
respectively. For each of the risk stratification methods,
ROC curves were used to evaluate its predictive perform-
ance. Area under the curve (AUC) was utilized as a sum-
mary measure for diagnostic accuracy of the prediction
tools across the gamut of risk groups [21], with 95% confi-
dence intervals (CI). For the comparison of clinical per-
formance of the risk scores, we chose to include AHA
high risk, Goldman high risk and two cutoffs of the TIMI
score (≥1 and ≥2). The latter were chosen pragmatically a
priori and attempted to balance case discrimination and
sensitivity. Inclusion of patients with a TIMI score of zero
provides no case discrimination, while using a cutoff of ≥3
has been shown to have a sensitivity <60% [22].
For all comparisons a p-value of <0.05 was considered
statistically significant. Statistical analysis was performed
with Stata, version 10 (College Station, TX, USA). Power
calculations were generated as follows: the AUC of the
TIMI score has previously been demonstrated to be 0.6
[23], while the Goldman score has been shown to have
an AUC of 0.9 [3,6]. The performance of the HFA score
was expected to be similar to that of the Goldman. As-
suming a correlation between positive and negative
groups of 0.4, a sample size of 400 patients was required
to distinguish an AUC of 0.85 from one of 0.9, at a p value
of 0.05 with an 80% power. An interim analysis was per-
formed as approved study duration and funding were
nearing their end. The study was terminated early as this
interim analysis revealed a clearly statistically significant
result. The institutional ethics committee approved the
study.Results
Two hundred eighty-one patients were studied with 276
completing 30-day follow-up. The median age of the
study group was 56 years (IQR 47.5-66), with the major-
ity (61.5%) being male (Figure 1). Patient characteristics
are summarized in Table 2. Of the 276 patients with 30-day
follow-up, 39 (14.1%) had a MACE.
The predictive performance of the risk stratification
tools is shown in Figure 2. AUC for prediction of MACE
was poorest for the HFA tool, with an AUC of 0.54 (95%
CI 0.45-0.63). The TIMI risk score had the highest AUC
of the three tools tested, with an AUC of 0.71 (95% CI
0.63-0.79), while the Goldman tool had an AUC of 0.67
(95% CI 0.57-0.77). The difference between the tools in
predictive ability for MACE was highly significant (p =
0.0002). There was no statistically significant difference
in performance between the Goldman tool and TIMI score.
The sensitivity and specificity of the tools are summarized
in Table 3.
Table 1 Risk stratification tools
Risk tool Risk category Features
HFA16 High risk Presentation with clinical features consistent with ACS and any of:
• Repetitive or prolonged (>10 min) ongoing chest pain/discomfort
• Elevation of at least one cardiac biomarker (troponin or CK-MB)
• Persistent of dynamic ST depression ≥0.5 mm or new T wave inversion ≥2 mm
• Transient ST segment elevation (≥0.5 mm) in more than two contiguous leads
• Hemodynamic compromise: systolic BP <90 mmHg, cool peripheries, diaphoresis, Killip class >1 and/or new
onset mitral regurgitation
• Sustained ventricular tachycardia or syncope
• Left ventricular systolic dysfunction (LVEF <40%)
• Prior PCI within 6 months or prior CABG
• Presence of known diabetes or chronic kidney disease (eGFR <60 ml/min) with typical symptoms of ACS
Intermediate risk Presentation with clinical features consistent with ACS and any of:
• Chest pain or discomfort within the past 48 h that occurred at rest or was repetitive or prolonged (but
currently resolved)
• Age >65 years
• Known coronary artery disease: prior MI with LVEF ≥40% or known coronary lesion >50% stenosis
• No high-risk ECG changes
• Two or more of: known hypertension, family history, active smoking and hyperlipidemia
• Presence of known diabetes or chronic kidney disease (eGFR <60 ml/min) with atypical symptoms of ACS
• Prior aspirin use
AND NOT meeting the criteria for high-risk NSTEACS
Low risk Presentation with clinical features consistent with ACS without intermediate- or high-risk features
• Onset of angina symptoms within the last month
• Worsening in severity or frequency of angina
• Lowering in angina threshold
TIMI RS19 1 point for each
positive factor
• Age >65 years
• Documented prior coronary artery stenosis >50% or prior cardiac catheterization with known disease or PCI or
prior CABG or documented prior myocardial infarction
• 3 or more conventional cardiac risk factors (hypertension, diabetes, cholesterol elevation, family history of
coronary artery disease/MI, history of tobacco use)
• Use of aspirin in the preceding 7 days
• 2 or more angina events in the past 24 h
• ST-segment elevation or depression >1 mm
• Elevated cardiac biomarkers
Goldman6 Very low risk • No ECG evidence of acute ischemia/MI and none of the following urgent factors:
▪ Rales above both lung bases
▪ Systolic BP <100 mmHg
▪ Unstable IHD (worsening of previously stable angina, new onset of post-infarction angina or angina after a
coronary revascularization procedure or pain that was the same as associated with a prior MI)
Low risk No ECG evidence of acute ischemia/MI and 1 of above urgent factors
Moderate risk No ECG evidence of acute ischemia/MI and 2 or 3 of above urgent factors
OR ECG evidence of acute ischemia AND 0 or 1 of above urgent factors
High risk ECG evidence of AMI alone OR ECG evidence of acute ischemia with 2 or 3 of above urgent factors
Abbreviations: ACS acute coronary syndrome, BP blood pressure, CABG coronary artery bypass graft, CK-MB creatine kinase-MB, ECG electrocardiograph, eGFR estimated
glomerular filtration rate, LVEF left ventricular ejection fraction, MI myocardial infarction, NSTEACS non-ST elevation acute coronary syndrome, PCI percutaneous
coronary intervention.
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Screened for enrolment 446
Enrolled = 281 
Completed 30 day follow-up = 276
Lost to follow-up =5
Exclusions = 168
No contact method = 3
STEMI =15
Lacked capacity = 33
Age <30 =18
Cardiac arrest =1
Definitive non cardiac cause =1
Figure 1 Patient enrollment.
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TIMI, Goldman and HFA tools, the difference between the
tools in terms of predictive ability for MACE was found to
be highly significant (chi2, N = 276, p <0.0001). Further
analysis showed that the HFA tool performance was dif-
ferent from that of each of the other tools, which were
similar in performance.Table 2 Patient characteristics
Feature
Age (years; median, interquartile range)
Male (%)
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Troponin I > 0.04 ng/ml (%
Results of previous investigations Left ventricular ejection fra
Previous coronary artery d
Prior history of revascularization (%) Percutaneous coronary int
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In this study of ED patients with chest pain, where no
alternative non-ACS cause was apparent, none of the
tools under investigation were ideal. Characteristics of
an ideal tool for stratifying risk of chest pain in the ED
population would be that it has high sensitivity for risk









zyme inhibitors/angiotensin receptor blockers 37
52.3
artile range) 73 (64–88)
edian, interquartile range) 140 (126–155)
8.9
n or T wave inversion (%) 14.2
) 11
ction < 40% 2.8
isease with known > 50% stenosis (%) 20.9
ervention (%) 16
ft (%) 10.7
Figure 2 Predictive performance of risk stratification tools.
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ure to unnecessary investigations or interventions. It
would also have data elements that were non-subjective
or, at least, had high interobserver reliability. The TIMI
risk score had the best performance in stratifying risk
for MACE. However, utilizing a cutoff of ≥1 to achieve a
sensitivity of 97% resulted in a specificity of only 13%. A
higher cutoff of >3 would be required to achieve a more
acceptable specificity of 60%; however, the resultant sen-
sitivity of 74% is unacceptable. The sensitivity of the
Goldman score (69%) was insufficient to be useful in the
ED population, even with the lowest possible cutoff,
namely including all patients with a risk higher than
‘very low’ risk. The HFA risk stratification tool had an
AUC of 0.54, with 95% confidence intervals (0.45-0.63)
disturbingly encompassing an AUC of <0.5. Its sensitiv-
ity for MACE, using a cutoff to include all high-risk pa-
tients, was 100%, but clearly with a specificity of 8%, its
feasibility in ED clinical practice is limited.
The use of an unstructured or individualized approach
to ED assessment of chest pain has been shown to be as-
sociated with high resource utilization for patients with
no coronary artery disease, while concurrently resulting
in significant proportions of patients with ACS being
missed [24]. Subsequently, emphasis has been placed on
utilization of risk stratification tools. Unfortunately,
studies employing risk stratification tools for chest pain
in the ED setting often have two significant limitations.Table 3 Comparative performance of risk stratification tools




HFA All high-risk patients 100 (91–100) 8
Goldman All patients with a risk category
of low or higher
69 (52–83) 5
TIMI RS TIMI RS of ≥1 97 (87–100) 1
TIMI RS ≥2 90 (76–97) 3First, the tools employed have largely been designed for
risk stratification of those with known ACS, usually pa-
tients admitted to the hospital. Utilizing these tools in
the undifferentiated ED patient with chest pain may have
a significant impact on both safety and efficiency. Sec-
ond, many trials of chest pain risk stratification have
tested the tools on ED populations where their chest
pain is “thought to be of ischaemic origin.” However, as
physician discrimination of ACS from other causes of
chest pain has previously been shown to be poor, this
may result in potentially flawed inferences [24].
The TIMI tool is widely reported as being utilized in
the undifferentiated chest pain population in the ED, in-
cluding as part of rapid diagnostic protocols [25]. In this
study, TIMI had comparable sensitivity and specificity
for MACE to that found in previously published studies
[25], but again highlights that the selection of an appro-
priate cutoff, balancing sensitivity, specificity and clinical
feasibility, is problematic.
Earlier studies identified a higher sensitivity for the
Goldman tool in the ED setting than our results [3,26].
This disparity may be accounted for by the fact that
these studies differed in their inclusion criteria, with a
focus on patients admitted to the hospital, including pa-
tients with ST elevation MI, and/or had much earlier
follow-up for the endpoint of MACE. Additionally, both
the definition of MI and the available cardiac biomarkers
have changed considerably since these earlier studies.
The HFA risk stratification tool had an AUC of 0.54.
Its high sensitivity for MACE (100%) came at the cost of
a specificity of only 8.4%, reflecting classification of 93%
of patients as being at “high risk.” This finding is concord-
ant with a previously published study, which similarly
questioned the HFA risk stratification tool’s suitability for
use in this patient cohort [18]. If the HFA decision sup-
port tool [16] were applied to the patient population in
this study, it would lead to 93% of ED chest pain patients
being admitted to hospital wards and receiving treatments
such as heparin. The weight of evidence suggests that the
HFA risk stratification tool is inappropriate for use in
chest pain pathways in the unselected ED chest pain
population.
Other approaches to risk stratification of ED chest pain







.4 (5.2–12.7) 1.09 0.54 (0.45–0.63) 0.39
1 (45–58) 1.43 0.67 (0.57–0.77) 0.0007
3 (8.7–18) 1.12 0.71 (0.63–0.79) <0.0001
9 (33–46) 1.48
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experience and literature review rather than database
methods. It has five components – history, ECG, age, risk
factors and troponin level – which are each rated 0, 1 or 2
based on criteria. In a validation study, it was shown to
have better discriminative performance than the GRACE
and TIMI risk scores [27]. In multicentre validation, a low
HEART score (≤3) had a 1.7% rate of MACE [28]. Of con-
cern is that this score relies in part on subjective assess-
ment of likelihood of ACS for which inter-rater data are
scarce.
Another approach was taken by the GRACE investiga-
tors with the development of a score aimed at predicting
the absence of MACE. The GRACE freedom from
events score [29] was developed in an admitted chest
pain cohort with likely ACS and has undergone limited
external validation on admitted chest pain cohorts
[30,31]. No validation in an ED chest pain cohort has yet
been published.
A similar approach has been taken in the development
of the North American Chest Pain Rule (NACPR) [32].
It aims to identify low-risk ED chest pain patients suit-
able for early discharge. The rule consists of the absence
of five predictors—ischemic ECG changes not known to
be old, history of coronary artery disease, pain typical for
ACS, initial or 6-h troponin level greater than the 99th
percentile and age greater than 50 years. In internal val-
idation, it was 100% sensitive (95% confidence interval
97.2% to 100.0%) and 20.9% specific (95% confidence
interval 16.9% to 24.9%) for a cardiac event within
30 days, with 11% of patients being defined as low risk
[32]. Its utility has been challenged in an external valid-
ation study and comparison to the HEART score [33].
The NACPR identified 4.4% (95% CI 3-6%) for early dis-
charge with 100% (95% CI 98-100%) sensitivity for ACS,
while the HEART score identified 20% (95% CI 18-23%)
for early discharge with 99% (95% CI 97-100%) sensitiv-
ity for ACS. The low proportion of patients identified as
low risk in a population with MACE of 22% is a serious
threat to this score’s clinical utility. That said, the ap-
proach of trying to decide who is safe for discharge ra-
ther than identification of high risk is worthy of further
exploration.
This study has some limitations that should be consid-
ered in interpreting the results. Bias in the verification of
events is possible if the inability to contact patients in
follow-up coincided with those having events. The po-
tential for verification bias has been minimized by
follow-up not only via chart review but also via admis-
sions registry review and with the patient or proxy.
While most data were collected prospectively, some
were collected retrospectively and so are subject to po-
tential data omission. Some of the data were reliant on
patient self-report (e.g., of past history and risk factors).If available in the chart, this was verified; however, other-
wise, no attempt was made to verify these data, reflect-
ing the real-world ED clinical interaction. The study was
conducted at a single site, and this may have impacted
the external validity.
Conclusions
The TIMI risk stratification score appeared most suitable
for use in an undifferentiated ED chest pain population,
but selection of an appropriate cutoff is problematic. This
study highlights the need for validated risk stratification
tools for the ED chest pain cohort that examine not only
their safety in terms of their sensitivity, but also their flow
and efficiency impacts, as these factors have significant
implications for safety for all ED patients.
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